Acute myelogenous leukemia


There is significant controversy with regards to the role of an allogeneic and autologous stem cell transplant in first remission in the management of acute myeloid leukemia (AML). There is also limited data about the use of these procedures and the clinical outcome when used in the Asian continent. In this proposed study we plan to attempt:

  1. Through a questionnaire to major centers in Asia, that regularly treat acute myeloid leukemia, document there practices and note the algorithms used for utilization of a stem cell transplant.
  2. From the major transplant centers we hope to document the number of allogeneic and autologous SCT done over the last 5 years for AML in CR1.
  3. From the transplant center data document the following key details:
    1. Conditioning regimens used with specific relevance to myeloablative vs. non myeloablative regimens
    2. Gvhd prophylaxis regimens
    3. Cumulative incidence of acute and chronic GVHD
    4. Cumulative incidence of relapse. Event free and overall survival
  4. For long term survivors we will attempt to apply a quality of life questionnaire.



Chairman: Vikram Mathews (India)